Incorporating NGS sequencing results as an integral biomarker in a clinical trial of neoadjuvant radiotherapy and a radiosensitizer is feasible.Clinical trial information: NRG-DT001 NCT03217266.Meng Xu WelliverThe Ohio State University James Cancer Center, Columbus, OH;Pedro A. Torres-Saavedra...